Comparison of Two Botulinum Toxin Type A Preparations for Treating Crow's Feet: A Split-Face, Double-Blind, Proof-of-Concept Study

Prager, Welf; Wissmüller, Esther; Kollhorst, Bianca; Williams, S.; Zschocke, I.

doi:10.1111/j.1524-4725.2010.01798.x

Cited by 48 publications

(30 citation statements)

References 23 publications

(52 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, the total dosages for both products were similar and low, as expected for cosmetic procedures in the face. Therefore, the results from this large retrospective study (n = 1256) are in line with published results of smaller prospective clinical studies which have shown similar efficacy of incobotulinumtoxinA compared with onabotulinumtoxinA in the treatment of glabellar frown lines in 381 subjects,7 crow’s feet in 21 subjects,6 and forehead lines in 12 subjects9 in aesthetic indications using identical dosages, as well as in therapeutic indications with similar dosages 10,11…”

Section: Discussionsupporting

confidence: 86%

“…Furthermore, in a large head-to-head study comparing incobotulinumtoxinA with onabotulinumtoxinA for the treatment of glabellar frown lines, the percentage of responders 4 and 12 weeks after injection of the same number of units (U) of either preparation were similar, and demonstrated that both treatments were highly effective according to the assessment of independent raters, investigators, and subjects 7. No statistically significant difference in efficacy was observed in a proof-of-concept study in the treatment of crow’s feet6 and in the treatment of forehead lines9 using a 1:1 dose ratio of the two products.…”

Section: Introductionmentioning

confidence: 97%

See 1 more Smart Citation

Botulinum toxin type A treatment to the upper face: retrospective analysis of daily practice

Prager¹,

Huber-Vorländer²,

Taufig³

et al. 2012

CCID

Self Cite

View full text Add to dashboard Cite

BackgroundBotulinum toxin type A treatment has been used for over 20 years to enhance the appearance of the face. There are several commercially available botulinum toxin type A products used in aesthetic clinical practice. The aim of this retrospective analysis was to compare the clinical efficacy of the most commonly used botulinum toxin type A preparations in daily practice.MethodsPhysicians from 21 centers in Germany completed questionnaires based on an inspection of subject files for subjects 18 years of age or over who had received at least two, but not more than three, consecutive treatments with incobotulinumtoxinA, onabotulinumtoxinA, or abobotulinumtoxinA within a 12-month period in the previous 2 years. Data on subject and physician satisfaction, treatment intervals, dosages, and safety were collected from 1256 subjects.ResultsThere were no statistically significant differences between incobotulinumtoxinA and onabotulinumtoxinA with respect to physician and subject satisfaction, dosages, and adverse effects experienced. Both botulinum toxin type A preparations were well tolerated and effective in the treatment of upper facial lines. Due to low treatment numbers, abobotulinumtoxinA was not included in the statistical analysis.ConclusionThe results of this retrospective analysis confirm the results of prospective clinical trials by demonstrating that, in daily practice, incobotulinumtoxinA and onabotulinumtoxinA are used at a 1:1 dose ratio and display comparable efficacy and safety.

show abstract

Section: Discussionsupporting

confidence: 86%

Section: Introductionmentioning

confidence: 97%

Botulinum toxin type A treatment to the upper face: retrospective analysis of daily practice

Prager¹,

Huber-Vorländer²,

Taufig³

et al. 2012

CCID

Self Cite

View full text Add to dashboard Cite

show abstract

“…The safety results show that incobotulinumtoxinA treatment was well tolerated, as reported previously,6,7,19 and no serious AEs – or any deemed to be related to the study drug – occurred.…”

Section: Discussionsupporting

confidence: 81%

Onset, longevity, and patient satisfaction with incobotulinumtoxinA for the treatment of glabellar frown lines: a single-arm, prospective clinical study

Prager¹,

Bee²,

Havermann³

et al. 2013

CIA

Self Cite

View full text Add to dashboard Cite

BackgroundIncobotulinumtoxinA (Bocouture®) is free from complexing proteins and effective for treating glabellar frown lines.PurposeTo determine the efficacy, onset, and duration of action of incobotulinumtoxinA for the treatment of glabellar frown lines.Patients and methodsIn this single-arm, prospective, proof-of-concept study, 23 patients were treated with 25 U incobotulinumtoxinA, equally split between five injection sites in the glabella. Severity of glabellar frown lines was rated by an independent rater from standardized photographs using the validated Merz 5-point scale at several visits over 5 months following treatment. To assess patient satisfaction, patients completed a questionnaire before and 2 weeks after treatment.ResultsThe percentage of responders at maximum frown 2–4 days after treatment was 95.2% and 85.0% when responders were defined as patients with ≥1-point and ≥2-point improvement on the 5-point scale compared with baseline, respectively. At this time point, 84% of the maximum effect had occurred. The responder rate at maximum frown, according to both definitions, was 100% for at least the next two visits (days 8 ± 1 and 14 ± 2). At all visits, the change from baseline in the mean glabellar frown-line score at maximum frown was statistically significant, with on average an almost 1-point improvement from baseline 5 months after treatment.ConclusionIncobotulinumtoxinA is an effective and well-tolerated treatment for glabellar frown lines, with a rapid onset of action and a long duration of effect lasting for more than 5 months.

show abstract

“…Die Wirkungsdauer für die Behandlung von "Krähenfüßen" wird mit 3 Monaten angegeben [57], die der Stirnfalten mit 3-4 Monaten [79,80]. Vergleichsstudien der einzelnen Produkte haben bezüglich der Wirkungsdauer ebenso widersprüchliche Ergebnisse ergeben, so dass in diesem Zusammenhang zur genauen Klärung weitere prospektive Studien mit großen Fallzahlen notwendig sind [51,[80][81][82].…”

Section: Wirkungseintritt Und Wirkungsdauerunclassified

S1‐Leitlinie Ästhetische Botulinumtoxin‐Therapie

Imhof

Sommer²

2013

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Die Leitlinie wurde im Auftrag der Deutschen Gesellschaft für Dermatochirurgie (DGDC) und der Deutschen Dermatologischen Gesellschaft (DDG) in Zusammenarbeit mit der Deutschen Gesellschaft für Ästhetische Botulinumtoxin-Therapie (DGBT) erstellt. Es wurde die Entwicklungsstufe S 1 ausgewählt. Die Methodik dieser S1-Leitlinie folgt den Vorgaben der Arbeitsgemeinschaft Wissenschaftlicher Medizinischer Fachgesellschaften (AWMF). Sie beruht auf aktuellen wissenschaftlichen Erkenntnissen und in der Praxis bewährten Verfahren. EinleitungDer Wunsch des Menschen nach Schönheit und Ästhetik ist keineswegs nur eine aktuelle Modeerscheinung, er zieht sich vielmehr durch alle Zeitalter und Kulturen. Bereits Platon beschreibt die zwei essentiellen Wünsche des Menschen, Gesundheit und Schönheit. Verbesserungen von Technik und Material im vergangenen Jahrhundert führten zu einer zunehmenden Verbreitung ästhetischer Eingriffe. Insbesondere nicht invasive, hautverjüngende ästhetische Maßnahmen gewinnen heutzutage weltweit zunehmend an Bedeutung.Vor über 20 Jahren beschrieben Carruthers und Carruthers erstmalig die Anwendung von Botulinumtoxin A (BTX-A) zur Behandlung der Zornesfalte [1][2][3].Der Einsatz von BTX-A zu ästhetischen Zwecken hat das Behandlungsspektrum der ästhetischen Dermatologie und der gesamten ästhetischen Medizin in dieser Zeit revolutioniert und deutlich erweitert. Dabei haben sich die Behandlungsziele zunehmend ausgeweitet, aber auch verfeinert [4].

show abstract

Comparison of Two Botulinum Toxin Type A Preparations for Treating Crow's Feet: A Split-Face, Double-Blind, Proof-of-Concept Study

Abstract: Both botulinum toxin A products displayed high efficacy and good tolerability at a dose ratio of 1:1, with no statistically significant differences between them. The high response rates observed after 4 months suggest a good effectiveness beyond this observation period.

Cited by 48 publications

References 23 publications

Botulinum toxin type A treatment to the upper face: retrospective analysis of daily practice

Botulinum toxin type A treatment to the upper face: retrospective analysis of daily practice

Onset, longevity, and patient satisfaction with incobotulinumtoxinA for the treatment of glabellar frown lines: a single-arm, prospective clinical study

S1‐Leitlinie Ästhetische Botulinumtoxin‐Therapie

Contact Info

Product

Resources

About